Literature DB >> 22801669

T-cell therapy in the treatment of post-transplant lymphoproliferative disease.

Catherine M Bollard1, Cliona M Rooney, Helen E Heslop.   

Abstract

Post-transplant lymphoproliferative diseases (PTLD) associated with Epstein-Barr virus (EBV) infection often develop after organ and haematopoietic stem-cell transplantation. These lymphoproliferative diseases are tumours that usually express all latent EBV viral proteins, and are therefore amenable to T-cell-based immune therapies, such as donor lymphocyte infusions and the adoptive transfer of EBV-specific cytotoxic T lymphocytes. In this Review, we describe current approaches of T-cell-based therapies to treat PTLD, and describe strategies that improve the feasibility of such treatment.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22801669      PMCID： PMC3743122          DOI： 10.1038/nrclinonc.2012.111

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  77 in total

Review 1.  Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines.

Authors:  Anne Parker; Kristin Bowles; J Andrew Bradley; Vincent Emery; Carrie Featherstone; Girish Gupte; Robert Marcus; Jayan Parameshwar; Alan Ramsay; Charles Newstead
Journal:  Br J Haematol       Date:  2010-04-16       Impact factor: 6.998

2.  NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

Authors:  Andrew D Zelenetz; Jeremy S Abramson; Ranjana H Advani; C Babis Andreadis; John C Byrd; Myron S Czuczman; Luis Fayad; Andres Forero; Martha J Glenn; Jon P Gockerman; Leo I Gordon; Nancy Lee Harris; Richard T Hoppe; Steven M Horwitz; Mark S Kaminski; Youn H Kim; Ann S Lacasce; Tariq I Mughal; Auyporn Nademanee; Pierluigi Porcu; Oliver Press; Leonard Prosnitz; Nashitha Reddy; Mitchell R Smith; Lubomir Sokol; Lode Swinnen; Julie M Vose; William G Wierda; Joachim Yahalom; Furhan Yunus
Journal:  J Natl Compr Canc Netw       Date:  2010-03       Impact factor: 11.908

3.  Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation.

Authors:  Tobias Feuchtinger; Kathrin Opherk; Wolfgang A Bethge; Max S Topp; Friedhelm R Schuster; Eva M Weissinger; Mohamad Mohty; Reuven Or; Michael Maschan; Michael Schumm; Klaus Hamprecht; Rupert Handgretinger; Peter Lang; Hermann Einsele
Journal:  Blood       Date:  2010-07-12       Impact factor: 22.113

Review 4.  Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

Review 5.  Posttransplant lymphoproliferative diseases.

Authors:  Thomas G Gross; Barbara Savoldo; Angela Punnett
Journal:  Pediatr Clin North Am       Date:  2010-04       Impact factor: 3.278

6.  Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects.

Authors:  J Joseph Melenhorst; Ann M Leen; Catherine M Bollard; Máire F Quigley; David A Price; Cliona M Rooney; Malcolm K Brenner; A John Barrett; Helen E Heslop
Journal:  Blood       Date:  2010-08-13       Impact factor: 22.113

Review 7.  Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines.

Authors:  Anne Parker; Kristin Bowles; J Andrew Bradley; Vincent Emery; Carrie Featherstone; Girish Gupte; Robert Marcus; Jayan Parameshwar; Alan Ramsay; Charles Newstead
Journal:  Br J Haematol       Date:  2010-04-16       Impact factor: 6.998

8.  Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.

Authors:  Juliet N Barker; Ekaterina Doubrovina; Craig Sauter; Jennifer J Jaroscak; Miguel A Perales; Mikhail Doubrovin; Susan E Prockop; Guenther Koehne; Richard J O'Reilly
Journal:  Blood       Date:  2010-09-08       Impact factor: 22.113

9.  Allo-HLA reactivity of virus-specific memory T cells is common.

Authors:  Avital L Amir; Lloyd J A D'Orsogna; Dave L Roelen; Marleen M van Loenen; Renate S Hagedoorn; Renate de Boer; Menno A W G van der Hoorn; Michel G D Kester; Ilias I N Doxiadis; J H Frederik Falkenburg; Frans H J Claas; Mirjam H M Heemskerk
Journal:  Blood       Date:  2010-02-16       Impact factor: 22.113

10.  Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells.

Authors:  Andreas Moosmann; Iris Bigalke; Johanna Tischer; Leah Schirrmann; Julitta Kasten; Stefanie Tippmer; Marina Leeping; Dusan Prevalsek; Gundula Jaeger; Georg Ledderose; Josef Mautner; Wolfgang Hammerschmidt; Dolores J Schendel; Hans-Jochem Kolb
Journal:  Blood       Date:  2010-01-26       Impact factor: 22.113
View more
  88 in total

1.  Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4+ and CD8+ T cell responses.

Authors:  Il-Kyu Choi; Zhe Wang; Qiang Ke; Min Hong; Yu Qian; Xiujuan Zhao; Yuting Liu; Hye-Jung Kim; Jerome Ritz; Harvey Cantor; Klaus Rajewsky; Kai W Wucherpfennig; Baochun Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205

2.  Combining drugs and biologics to treat nasopharyngeal cancer.

Authors:  Helen E Heslop
Journal:  Mol Ther       Date:  2014-01       Impact factor: 11.454

3.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report.

Authors:  Lindsay M Morton; Wael Saber; K Scott Baker; A John Barrett; Smita Bhatia; Eric A Engels; Shahinaz M Gadalla; David E Kleiner; Steven Pavletic; Linda J Burns
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-12       Impact factor: 5.742

Review 4.  T lymphocytes targeting native receptors.

Authors:  Cliona M Rooney; Ann M Leen; Juan F Vera; Helen E Heslop
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 5.  Exploiting the curative potential of adoptive T-cell therapy for cancer.

Authors:  Christian S Hinrichs; Steven A Rosenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 6.  Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?

Authors:  Christopher A Klebanoff; Luca Gattinoni; Nicholas P Restifo
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

Review 7.  Children's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma.

Authors:  Catherine M Bollard; Megan S Lim; Thomas G Gross
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

8.  The Epstein-Barr Virus Major Tegument Protein BNRF1 Is a Common Target of Cytotoxic CD4+ T Cells.

Authors:  Josef Mautner; Uta Behrends; Dinesh Adhikary; Julia Damaschke
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

9.  EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.

Authors:  M K Gandhi; T Hoang; S C Law; S Brosda; K O'Rourke; J W D Tobin; F Vari; V Murigneux; L Fink; J Gunawardana; C Gould; H Oey; K Bednarska; S Delecluse; R U Trappe; L Merida de Long; M B Sabdia; G Bhagat; G Hapgood; E Blyth; L Clancy; J Wight; E Hawkes; L M Rimsza; A Maguire; K Bojarczuk; B Chapuy; C Keane
Journal:  Blood       Date:  2021-03-18       Impact factor: 22.113

10.  Virology. Epstein-Barr virus turns 50.

Authors:  Paul M Lieberman
Journal:  Science       Date:  2014-03-21       Impact factor: 47.728
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.